Get started
Author

Barbara Valsasina

Observed names: B Valsasina, B. Valsasina, Barbara VALSASINA
ORCID: 0009-0003-4114-0907
Observed ORCID: 0009-0003-4114-0907
OpenAlex ID: A5062095629
Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death
2013 · Paola Magnaghi, Roberto D'Alessio, et al. · Nature Chemical Biology · 381
Structural Characterization of the GSK-3β Active Site Using Selective and Non-selective ATP-mimetic Inhibitors
2003 · J.A. Bertrand, S. Thieffine, et al. · Journal of Molecular Biology · 329
Identification of Mcm2 Phosphorylation Sites by S-phase-regulating Kinases
2006 · Alessia Montagnoli, Barbara Valsasina, et al. · Journal of Biological Chemistry · 227
PDF
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity
2008 · Alessia Montagnoli, Barbara Valsasina, et al. · Nature Chemical Biology · 208
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action
2017 · Elena Campaner, Alessandra Rustighi, et al. · Nature Communications · 155
NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
2012 · Barbara Valsasina, Italo Beria, et al. · Molecular Cancer Therapeutics · 125
NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor
2011 · Italo Beria, Roberto T. Bossi, et al. · Bioorganic & Medicinal Chemistry Letters · 110
Bean homologs of the mammalian glucose-regulated proteins: induction by tunicamycin and interaction with newly synthesized seed storage proteins in the endoplasmic reticulum.
1992 · L D'Amico, B Valsasina, et al. · The Plant Journal · 100
PDF
Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potential Antitumor Agents. 1. Synthesis and Structure–Activity Relationships
2008 · Ermes Vanotti, Raffaella Amici, et al. · Journal of Medicinal Chemistry · 93
Distinct Role of 2-O-, N-, and 6-O-Sulfate Groups of Heparin in the Formation of the Ternary Complex with Basic Fibroblast Growth Factor and Soluble FGF Receptor-1
1994 · M. Rusnati, D. Coltrini, et al. · Biochemical and Biophysical Research Communications · 87
Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors
2010 · Italo Beria, Dario Ballinari, et al. · Journal of Medicinal Chemistry · 84
Novel hirudin variants from the leech Hirudinaria manillensis
1993 · Emanuela SCACHERI, Gianpaolo NITTI, et al. · European Journal of Biochemistry · 79
First Cdc7 Kinase Inhibitors: Pyrrolopyridinones as Potent and Orally Active Antitumor Agents. 2. Lead Discovery
2008 · Maria Menichincheri, Alberto Bargiotti, et al. · Journal of Medicinal Chemistry · 69
Cdc7 Kinase Inhibitors: 5-Heteroaryl-3-Carboxamido-2-Aryl Pyrroles as Potential Antitumor Agents. 1. Lead Finding
2010 · Maria Menichincheri, Clara Albanese, et al. · Journal of Medicinal Chemistry · 63
Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo.
2010 · Ulisse Cucchi, Laura M Gianellini, et al. · PubMed · 60
Synthesis and Biological Evaluation of RGD Peptidomimetic–Paclitaxel Conjugates Bearing Lysosomally Cleavable Linkers
2015 · Alberto Dal Corso, Michele Caruso, et al. · Chemistry - A European Journal · 53
Cell Division Cycle 7 Kinase Inhibitors: 1H-Pyrrolo[2,3-b]pyridines, Synthesis and Structure−Activity Relationships
2009 · Antonella Ermoli, Alberto Bargiotti, et al. · Journal of Medicinal Chemistry · 53
The C‐terminal domain of yeast Ero1p mediates membrane localization and is essential for function
2001 · Massimiliano Pagani, Stefania Pilati, et al. · FEBS Letters · 49
A new approach to phosphoserine and phosphothreonine analysis in peptides and proteins: chemical modification, enrichment via solid-phase reversible binding, and analysis by mass spectrometry
2003 · Florian Thaler, Barbara Valsasina, et al. · Analytical and Bioanalytical Chemistry · 47
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors
2017 · Glen J. Weiss, Gayle Jameson, et al. · Investigational New Drugs · 42
Characterization of a saporin isoform with lower ribosome-inhibiting activity
1997 · M. Serena FABBRINI, Emilia RAPPOCCIOLO, et al. · Biochemical Journal · 41
The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia
2013 · Alessia Casolaro, Josee Golay, et al. · PLoS ONE · 35
PDF
Recombinant Human Il-2 Is Cytotoxic to Oligodendrocytes After in Vitro Self Aggregation
1997 · L. Curatolo, B. Valsasina, et al. · Cytokine · 35
Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance
2014 · Valeria Sero, Elisa Tavanti, et al. · Investigational New Drugs · 34
Inhibitor affinity chromatography: Profiling the specific reactivity of the proteome with immobilized molecules
2003 · Graziano Lolli, Florian Thaler, et al. · PROTEOMICS · 34
Works count: 101
Citation count: 3,013
H-index: 28
I10-index: 42
Year
Topic
Type